The effect of vitamin C on morphine self-administration in rats
Mahboobeh Talkhooncheh1, Hojjat Allah Alaei2, Effat Ramshini2, Somaei Shahidani2
1 Department of Biology, Isfahan University, Isfahan, Iran
2 Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
|Date of Submission||30-May-2012|
|Date of Acceptance||19-Dec-2012|
|Date of Web Publication||26-Aug-2014|
Hojjat Allah Alaei
Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan
Source of Support: None, Conflict of Interest: None
Clinical trial registration abr_243_12
Background: Recent studies have shown that addiction may be caused by abnormality of neurotransmission in the brain. Two neurotransmitters that involve into morphine addiction are dopamine and glutamate. The glutamatergic and dopaminergic systems are also involved in morphine tolerance and morphine withdrawal syndrome signs. Ascorbic acid (AA), as the antioxidant releases from the glutamatergic neurons, modulates the action of the dopamine and glutamate systems. In this study, the effect of AA on morphine self-administration and morphine withdrawal symptoms has been investigated.
Materials and Methods: Male Wistar rats (250 - 300g) were anesthetized with ketamine (11%) and xailazine (15%). The cannula was inserted into the right jugular vein, and it was fixed subcutaneously on the skull. After surgery the animals were placed in individual home cages, and they were allowed to recover from the operation for five days, before the test. The animals were subjected to self-administration morphine for12 consecutive days, two-hour/sessions. The number of infusions and number of active and passive lever pressings were recorded.
Results: An intra peritoneal injection of Ascorbic acid (AA) (400 mg/kg, i.p.), 30 minutes before morphine self-administration, produced a significant decrease in 12 days self-administration of morphine and withdrawal syndrome signs (P < 0.05).The morphine withdrawal signs (MWS) were recorded after naloxone precipitation, which decreased significantly with the injection of AA (400,700mg/kg), (<0.05). The number of self-infusions and the number of active lever pressings had significantly decreased after AA injection (P < 0.05).
Conclusion: The chronic administration of AA may prevent the development of tolerance and physical dependence on morphine self-administration via the glutamatergic system.
Keywords: Ascorbic acid, morphine, rat, self-administration
|How to cite this article:|
Talkhooncheh M, Alaei HA, Ramshini E, Shahidani S. The effect of vitamin C on morphine self-administration in rats. Adv Biomed Res 2014;3:178
|How to cite this URL:|
Talkhooncheh M, Alaei HA, Ramshini E, Shahidani S. The effect of vitamin C on morphine self-administration in rats. Adv Biomed Res [serial online] 2014 [cited 2017 Oct 18];3:178. Available from: http://www.advbiores.net/text.asp?2014/3/1/178/139524
| Introduction|| |
Both acute and chronic administration of morphine affects the turnover of the classical brain neurotransmitter, dopamine. On the other hand, the glutamatergic system is also involved in morphine tolerance and abstinence. , It has been shown that the reinforcing effects of drug abuse are modulated by the administration of morphine, in animals.  Several studies have documented that MK-801(antagonist glutamate) inhibits cocaine self-administration in animals  and reverses its facilitation after chronic exposure to amphetamine.  AP5 (antagonist glutamate) increases the lever pressings for cocaine when administered into the nucleus accumbens (NAC).  Ascorbic acid is an antioxidant vitamin that has been an antagonist in the glutamatergic and dopaminergic systems.  A recent study has indicated that AA is released from glutamatergic neurons as a part of the glutamate reuptake process, in which the high-affinity glutamate transporter exchanges AA for glutamate.  AA plays an important role in the modulating action of the glutamatergic  and dopaminergic  systems, as well as in the behavior.  Low doses of AA can increase the neuronal activity and induce public neuronal oxidative stress on the primary cortical neurons.  The divergent effects of the overdoses of AA on the neuronal activity provide a change from the presynaptic facilitator of glutamate transmission, at relatively low extracellular concentration, to the discontinuation of postsynaptic glutamate receptors.  The high dose of AA also decreases the withdrawal symptoms in the opiate addicts,  changes the motivational process underlying morphine self-administration, and prevents the development of tolerance and physical dependence on morphine, in mice. , Both the glutamatergic and dopaminergic systems are involved in the dependence and tolerance of morphine and morphine withdrawal syndrome signs,  and all these treatments are majorly affected by AA. , From the previous studies it is not clear as to what dose of AA can prevent tolerance to opioids (especially morphine). Therefore, in this investigation we endeavor to determine the effect of low and high doses of AA on self-administration of morphine as well as on morphine withdrawal symptoms, in rats.
| Materials and methods|| |
Morphine (HCl) was obtained from TEMD Ltd. Tehran, Iran.
Ascorbic acid was purchased from Merck, Germany. Morphine and ascorbic acid were dissolved in saline. Naloxone hydrochloride was obtained from Jaber EbnHaian, Tehran, Iran.
The male Wistar rats (n = 30) were divided randomly into three groups as follows:
- Control group (n = 10), received normal saline in the self-administration, for 12 consecutive days, two-hour/session
- Morphine group (n = 10) received morphine (HCl) in saline solution (5mg/ml) during the self-administration for 12 consecutive days, two-hour/session
- Ascorbic acid + morphine group (n = 10) received both AA (400mg/kg, i.p) 30 minutes before each session and morphine in the self-administration for 12 consecutive days, two-hour/session.
Animals and housing conditions
Male Wistar rats (250-300g) were housed individually and received food and water ad libitum. The animals were maintained under a day-night cycle with lights on between 08:00 and 20:00 hours. After surgery, the animals were returned to their individual home cages and allowed to recover from the operation for five days before the test. The day-night cycle was reversed for four days before thetests, and the experiments were done during the dark phase of the cycle.
The rats were anaesthetized with ketamine (11%) and xailazine (15%). The cannula filled with heparin-saline was inserted into the right jugular vein and it was guided subcutaneously up to the skull. The cannula was fixed on the skull with metal screws and dental acrylic cement.
The experiment was done in a standard metal cage (21cm*21cm*28 cm) placed in a sound attenuated room. The test metal cage had two levers (active and passive) that were 2 cm above the floor, and a red light located 4 cm above the active lever. The rat i.v cannula was connected to the infusion peristaltic pump and pressing of the active lever, marked by the red light, resulted in an i.v infusion of 0.1 ml fluid (5 mg/ml morphine (HCl) in saline) for 10-12 seconds. The pressing of the passive lever had no i.v infusion. The animals were allowed to self-administer morphine for 12 consecutive days, two hours/session.For all groups during the first five days, when the animals pressed to active lever, they received foods and saline (control groups) or morphine (morphine, morphine + AA groups), on the other days when the animals pressed to active lever, they received saline (control groups) or morphine (morphine, morphine + AA groups). Thenumber of lever pressings was recorded by the computer and analyzed by a special program.
Withdrawal syndrome signs
Acute and chronic effect of ascorbic acid
Male Wistar rats (n = 24) were tested in four groups as follows:
- Control group (n = 6) received 0.2 ml normal saline for nine consecutive days
- Morphine group (n = 6) received morphine (10 mg/kg, 20 mg/kg, 40 mg/kg) for nine consecutive days; the first three days 10 mg/kg, the second three days 20 mg/kg, and the third three days 40 mg/kg 
- Morphine + AA group (n = 6) received morphine (10mg/kg, 20mg/kg, 40mg/kg) for nine consecutive days, and on the tenth day, they received ascorbic acid (400,700 mg/kg, i.p) for evaluating the effects of AA on the morphine withdrawal syndrome signs (MWS). At the end of the training period, all the animals were put into abox made of fiber glass, and the signs of withdrawal were controlled and measured for 30 minutes after injection of naloxone (2 mg/kg, i.p).
The control and morphine groups are the same, with an acute effect of AA. In the groups three animals received 400 mg/kg AA before injection of morphine for nine consecutive days. The signs of withdrawal were measured for 30 minutes after injection of naloxone (2 mg/kg, i.p) on the tenth day.
Comparison between the two groups was performed using the unpaired Student's t-test. Comparisons among several groups were performed using one-way analysis of variance (ANOVA) and the post-hoc test (Turkey). A value of P < 0.05 was considered statistically significant.
| Results|| |
0Initiation of drug self-administration
Our results indicated that the number of active lever pressings in the three groups were significantly different within the groups [Figure 1], P < 0.05]. The total number of active lever pressings was increased between the morphine group and the control group. After administration of ascorbic acid, the number of active lever pressings started to decrease significantly from the fifth day until the twelfth day, when compared to the morphine group (P < 0.05).
|Figure 1: The number of active lever pressings in the three groups (control, morphine, morphine AA): (a) There are significant differences between the morphine group and the other groups during the 12 days. (P < 0.05, N = 10, X ± SEM). The number of lever pressings is decreased after injection of AA from the fifth to the twelfth days. (b) the total number of active lever pressings in the three groups of experiments: There is a significant difference between the morphine alone and the control and morphine + AA groups. (X ± SEM, P < 0.05). Confidence interval (CI) Morphine, morphine + AA: 9.407 < CI < 13.955 Morphine, control: 8.306 < CI < 12.971 Morphine + AA, control: -1.927 < CI < 0.152|
Click here to view
There was no significant difference between the number of self-administrations in the three groups in the earliest days (the first, second and third days). After five days, a significant difference was observed among the number of self- administrations in the three groups [Figure 2], P < 0.05]. Self-administration in the AA + morphine group was significantly less than that in the morphine group (P < 0.01).
|Figure 2: The number of self-administrations in three groups of experiments. There is no significant difference between the AA + morphine and control groups. The number of infusions in the AA + morphine group is decreased in comparison to the morphine group (P < 0/05, N = 10, X ± SEM)|
Click here to view
There was no significant difference among the number of passive lever pressings in the three groups during the 12 days [Figure 3], P > 0.05]. The total number of passive lever pressings also did not have significant changes between the morphine group and the other groups. The numbers of active and passive lever pressings were compared between each group of rats. These results indicated that the number of active lever pressings increased significantly in the morphine group (P < 0.05), but after injection of ascorbic acid decreased in the morphine + AA group [Figure 4].
|Figure 3: The number of passive lever pressings in three groups of experiments:(a) There is no significant difference between morphine, AA + morphine, and the control groups during the 12-dayself-administration session. (N = 10, X ± SEM);(b) there is no significant difference between the morphine, control, and morphine + AA groups in the total number of passive lever pressings. (P < 0.05) X ± SEM. Confidence interval morphine, morphine + AA: -0.431 < CI < 1.126 Morphine, control: -0.829 < CI < 0.042 Morphine + AA, control: -1.571 < CI < 0.819|
Click here to view
|Figure 4: The total number of passive and active lever pressings was compared between each group. The active lever pressing was significantly higher than the passive only in the morphine group (P < 0.05). The total number of active lever pressing reduced after injection of AA and there was no significance with passive lever pressing in the morphine + AA group|
Click here to view
Our results showed that intraperitoneal administration of AA (400 mg/kg, i.p) prevented the development of tolerance and dependence on morphine. Injection of ascorbate could antagonize the reinforcing effect of morphine and could be used as an effective pharmacotherapy for morphine abuse, especially when a high dose was used.
Withdrawal syndrome signs
Results from the effect of acute and chronic ascorbic acid on the abstinence syndrome are shown in [Table 1]. In these results, the control group did not show any of the defined withdrawal signs. Most of the signs were reduced after acute injection of AA, especially teeth chattering, wet dog shakes, elongated body posture, and climbing, in comparison to these signs in the morphine group. Chronic administration of AA before injection of morphine for nine days greatly attenuated the withdrawal signs like climbing, teeth chattering, licks, and wet dog shaking, in morphine-addicted rats, but it had no effect on jumping or diarrhea.
|Table 1: The effect of ascorbic acid on the morphine withdrawal signs during the 30 minutes after injection of naloxone|
Click here to view
| Discussion|| |
In this study, the injection of AA (400 mg/kg, i.p) 30 minutes before the self-administration session caused a decrease in the number of active lever pressings to obtain morphine [Figure 1]. The tolerance in the groups had decreased significantly in rats receiving AA in comparison tothe morphine-addicted animals [Figure 1]. A previous study showed the effect of AA on morphine self-administration and morphine tolerance according to various doses.  The results indicated that 400 mg/kg of AA changed morphine withdrawal signs and morphine dependence, but 700 mg/kg of AA changed morphine tolerance without effect on the signs of active lever pressing, after morphine injection, during self-infusion [Figure 2], tab. These results showed that various doses of AA produced different tolerance and withdrawal signs [Table 1]. We had determined that the animals would die if AA of more than of 700 mg/kg was used. This dose of AA, might enhance the activity of the dopaminergic system and create a problem for the animals and humans. This was a novel finding of this experiment. Evanelou and Kalfakakou,(2000)  showed that withdrawal syndrome signs decreased in heroin addicts, with oral administration of high doses of AA. These studies indicated that the inhibitory effects of chronic AA administration on morphine withdrawal symptoms confirmed the previous findings in humans and mice. ,
The rat receiving repeated treatment with saline followed by various doses of morphine (10, 20, 40mg/kg) displayed numerous escape jumps in response to administration of noloxane (2 mg/kg, s.c.) on the tenth day. The rat treated with AA (400 mg/kg, i.p) followed by morphine for nine days showed a decrease in the incidence of escape jumps. However, this effect of AA was not significant.
It is possible that these symptoms were controlled by various mechanisms. It may also reflect a poor penetration of AA into the brain, which has been reported following acute systemic AA administration.  The process involves development of physical dependence on morphine, and suppression of tolerance and withdrawal response by chronic AA behavior is unknown.
Recent studies have reported that AA and morphine have opposite effects on membrane Na, K + - ATPase activity. Morphine has a stimulatory effect, whereas, AA has an inhibitory effect on this pump Na + , k + - ATPase. , It has been reported that an increase in the activity of Na, K + ATPase is partly responsible for the two major opiate effects in the brain, which create hyper polarization in the membrane and also inhibition of neurotransmitter release.  The AA dose dependently decreases the analgesic effect of morphine in mice,  and it may reduce the analgesic effect of morphine in patients. These results, along with others' knowledge, show that AA modulates the synaptic action of dopamine and glutamate, which suggests that even very high doses of AA, which are known to be non-toxic, may be used with dopaminergic antagonist drugs, to treat the morphine-abstinence syndrome.
| Acknowledgment|| |
The authors thank Prof. M Nematbakhsh for editing the text and S. Sadeghi for the technical assistance.
| References|| |
|1.||Siggins GR, Martin G, Roberto M, Nie Z, Madamba S, De Lecea L. Glutamatergic tranmission in opiate and alcohol dependence. Ann NY Acad Sci 2003;1003:196-211. |
|2.||Ozawa T, Nakagawa T, Sekiya Y, Minami M, Satoh M. Effect of gene transfer of GLT-1, a glutamate transporter, into the locus coerulesus by recombinant adenoviruses on morphine physical dependence in rats. Eur J Neurosci 2004;19:221-6. |
|3.||Aghajanian GK, Kogan JH, Moghaddam B. Opiate withdrawal increases glutamate and aspartate efflux in the locus ceoruleus: An in vivo microdialysis study. Brain Res 1994;636:126-30. |
|4.||Schenk S, Valadez A, Worley CM, Mcnamara C. Blokade of the acquisition of cocaine self-administration by the NMDA antagonist MK-801. Behav Pharmacol 1993;4:652-9. |
|5.||Schenk S, Valadez A, Worley CM, Mcnamara C, House DT, Higley D, et al. Development and expression of sensitization to cocaine's reinforcing properties: Role of NMDA receptors. Psychopharmacology (Berl) 1993;111:332-8. |
|6.||Alaei H, Esmaeili M, Nasimi A, Pourshanazari A. Ascorbic acid decrease morphine self-administrationand withdrawal symptoms in rats. Pathophysiology 2005;12:103. |
|7.||Alaei H, Esmaeily M. Low doses of ascorbic reduced withdrawal syndrome sign in rats. J Gazvin Univ 2001;5:24-9. |
|8.||Fan SF, Yazulla S. Modulation of voltage-dependent K+currents (IK (V)) inretinal bipolar cells by ascorbate is mediated by dopamine D1 resptors. Vis Neurosci 1999;16:923-31. |
|9.||Fornai F, Piaggi S, Gesi M, Saviozzi M, Lenzi P, Paparelli A, et al. Subcellular localization of a glutathione-dependent dehydroascorbatereductate within specific rat brain region. Neuroscience 2001;104:15-31. |
|10.||Garcia MM, Anderson AT, Edwards R, Harlan RE. Morphine induction of c-fos expression in the rat forebrain though glutamatergic mechanisms: Role of non-n-methyl-D-aspartate receptors. Neuroscience 2003;119:787-94. |
|11.||Bockaert J, Manzoni OJ, Robbe D. Metabortopic glutamate receptor 2/3-dependent long-term depression in the nucleus accombens is blocked in morphine- withdrawal mice. Eur J Neurosci 2002;16:2231-5. |
|12.||Popik P, Kozela E, Wrobel M, Wozniak KM, Slusher BS. Morphine dependence are inhibited by the selective glutamate carboxypeptidase 2 (GCP2, NAALADase) inhibitor, 2-Pmpa. Neuropsychopharmacology 2003;28:457-67. |
|13.||Xu NJ, Bao L, Fan HP, Bao GB, Pu L, Lu YJ, et al. Morphine withdrawal increases glutamate uptake and surface experssion of glutamate transporter GLT1 at hippocampal synapses. J Neurosci 2003;23:4775-84. |
|14.||Demidchchik V, Sokolik A, Yurin V. Characteristics of non-specific permeability and H+-ATPase inhibition induced in the plasma membrane of Nitellaflexilis by excessive Cu+. Planta 2001;212:583-90. |
|15.||Goldshleger R, Patchornik G, Shimon MB, Tal DM, Post RL, Karlish SJ. Structural organization and energy transduction mechanism of Na+, K+-ATPase studied with transition metal: Catalyzed oxidative cleavage. J Bioenerg Biomembr 2001;33:387-99. |
|16.||Evangelou A, Kalfakakou V. Ascorbic acid (vitamin C) effects on withdrawal syndrome of heroin abusers. In Vivo 2000;14:363-6. |
|17.||Hong M, Milne B. Evidence for the involvement of excitatory amino acid pathway in the development of precipitated withdrawal from acute morphine. Brain Res 1993;623:131-41. |
|18.||Koyuncuoglu H, Nurten A, Enginar N, Ozerman B, Kara I. The effects of different 4-aminopyridine and morphine combination on the intensity of morphine abstinence. Pharmacol Res 2001;43:245-50. |
|19.||Willette RE, Thomas BL, Barnett G. Inhibition of morphine analgesia by ascorbate. Res Commun Chem Pathol Pharmacol 1983;42:485-91. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]